Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab

Acta Ophthalmol. 2015 Sep;93(6):e511-2. doi: 10.1111/aos.12618. Epub 2014 Dec 9.

Authors

Archana Airody¹, Divya Venugopal¹, Victoria Allgar², Richard P Gale¹

Affiliations

¹ Academic Unit of Ophthalmology, York Teaching Hospitals NHS Foundation Trust, York, North Yorkshire, UK.
² Department of Health Sciences, University of York, York, North Yorkshire, UK.

PMID: 25488611
DOI: 10.1111/aos.12618

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Angiogenesis Inhibitors / therapeutic use*
Female
Follow-Up Studies
Humans
Intravitreal Injections
Male
Ranibizumab / therapeutic use*
Retina / pathology
Retrospective Studies
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / drug effects
Wet Macular Degeneration / drug therapy*
Wet Macular Degeneration / physiopathology

Substances

Angiogenesis Inhibitors
VEGFA protein, human
Vascular Endothelial Growth Factor A
Ranibizumab